• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Integra touts outcomes, cost-savings in wound-healing studies

Integra touts outcomes, cost-savings in wound-healing studies

May 18, 2020 By Nancy Crotti

(Image from Integra LifeSciences)

A pair of retrospective studies of an Integra LifeSciences (NSDQ:IART) wound-healing matrix showed positive clinical and economic results, the company announced on Friday.

The studies looked at the results of complex lower extremity reconstruction using Integra’s bilayer wound matrix. The data were published in Plastic and Reconstructive Surgery.

The bilayer wound-healing matrix is formulated to provide an environment where the body can rebuild the layers of the skin to support the healing process, according to Princeton, N.J.-based Integra.

The first clinical publication showed 70% of the wounds successfully salvaged at 180 days, allowing the authors to identify success factors across patient selection and wound types.

The second publication reviewed cost and resource use, comparing Integra’s bilayer wound matrix to local tissue rearrangement (LTR) and free flap (FF) tissue transplantation. This study showed significantly longer surgery time at 85 and 408 minutes for LTR and FF respectively, compared with 50 minutes for the Integra matrix.

It also reported more than double the length of stay in the hospital for both LTR and FF versus the Integra matrix. Lastly, total cost of the surgery was $53,492 for FF, $35,220 for LTR and $34,877 for the Integra product, the company noted.  Given the shorter operating time and the potential lower cost, Integra bilayer wound matrix may represent an opportunity for patients, surgeons and hospitals during the COVID-19 pandemic, according to the company.

The lower costs for procedures involving the Integra product could also be a boost for the company, which posted a nearly 72% profit slide for the three months ended March 31, 2020, due to the reduction of elective procedures during the pandemic.

Two plastic surgeons from the University of Pennsylvania Health System presented the data in a company webinar last week.

“Lower extremity reconstruction can be challenging and costly for both the patient and health care system,” said Dr. Stephen J. Kovach in a news release. “Our goal is to choose an appropriate treatment algorithm, including dermal constructs, that restores function while providing economic benefits.”

“In complex lower extremity reconstruction, no approach is completely effective in all situations and contexts, and our recent publications highlight the key scenarios where skin substitutes can be optimally positioned for maximal clinical success,” added Dr. John P. Fischer, director of clinical research at University of Pennsylvania Health System. “Our findings identify key relative advantages with respect to operative efficiency and hospital utilization that align with current issues caused by the COVID-19 pandemic.”

Filed Under: Clinical Trials, Featured, Hospital Care, Surgical, Wound Care Tagged With: Integra LifeSciences, University of Pennsylvania

More recent news

  • Mount Sinai adopts Flosonics wearable ultrasound device
  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy